期刊
CANCER DISCOVERY
卷 11, 期 8, 页码 1913-1922出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-21-0365
关键词
-
类别
资金
- Mark Foundation for Cancer Research EXTOL Project Grant
- Stand Up To Cancer-American Cancer Society Lung Cancer Dream Team Translational Research Grant [SU2C-AACR-DT17-15]
- NIH [1F32CA250231-01, R01-CA164273]
- US-JFCR Scientist Exchange Program
- AACR [19-20-45-BARP]
- NIH/NCI [R00 CA215249]
- [DRR-62-20]
This study described a patient with KRAS(G12C) non-small cell lung cancer who developed polyclonal acquired resistance to MRTX849 treatment. The research identified 10 heterogeneous resistance alterations that converged to reactivate the RAS-MAPK signaling pathway. Additionally, a novel KRAS(Y96D) mutation affecting key protein-drug interactions and driving resistance was discovered.
Mutant-selective KRAS(G12C) inhibitors, such as MRTX849 (adagrasib) and AMG 510 (sotorasib), have demonstrated efficacy in KRAS(G12C)-mutant cancers, including non-small cell lung cancer (NSCLC). However, mechanisms underlying clinical acquired resistance to KRAS(G12C) inhibitors remain undetermined. To begin to define the mechanistic spectrum of acquired resistance, we describe a patient with KRAS(G12C) NSCLC who developed polyclonal acquired resistance to MRTX849 with the emergence of 10 heterogeneous resistance alterations in serial cell-free DNA spanning four genes (KRAS, NRAS, BRAF, MAP2K1), all of which converge to reactivate RAS-MAPK signaling. Notably, a novel KRAS(Y96D) mutation affecting the switch-II pocket, to which MRTX849 and other inactive-state inhibitors bind, was identified that interferes with key protein-drug interactions and confers resistance to these inhibitors in engineered and patient-derived KRAS(G12C) cancer models. Interestingly, a novel, functionally distinct tricomplex KRAS(G12C) active-state inhibitor RM-018 retained the ability to bind and inhibit KRAS(G12C/Y96D) and could overcome resistance. SIGNIFICANCE: In one of the first reports of clinical acquired resistance to KRAS(G12C) inhibitors, our data suggest polyclonal RAS-MAPK reactivation as a central resistance mechanism. We also identify a novel KRAS switch-II pocket mutation that impairs binding and drives resistance to inactive-state inhibitors but is surmountable by a functionally distinct KRAS(G12C) inhibitor.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据